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Abstract  
Introduction: The aim of the study is to compare efficacy of IvIg versus PE in treatment of mechanically ventilation adults with GBS in intensive 
care unit. Methods: It is a prospective, non randomized study, realized in a medical ICU from 2006 to 2010. We included all patients with GBS 
who required mechanical ventilation (MV). We defined two groups: group 1 (group treated by IvIg: 0.4 g/kg/day for 5 days) and group 2 (group 
treated by PE: 4 PE during 10-14 days). We collected demographic characteristics, clinical and therapeutic aspects and outcome. Statistical analysis 
used: The quantitative variables are expressed on mean ± standard derivation and compared by Student test. The statistic analysis has been 
based on SPSS for windows. P < 0.05 is considered as significant. Results: Forty-one patients (21 in group 1 and 20 in group 2) were enrolled. 
The mean age was 37.4 ± 9.2 years, with a masculine predominance (75.4%). Electromyogram in all patients found acute inflammatory 
demyelinating polyradiculoneuropathy in 80.5 % of patients. The mean length of hospitalization was 45.3 ± 9.2 days. The length of hospitalization 
of the IvIg group is less long than PE group (p = 0.03). The weaning of the MV was more precocious in IvIg group than PE group (p = 0.01). Also, 
the beginning of motility recuperation was precocious at IvIg group than PE group (p = 0.04). Conclusion: Our work reveals a meaningful 
difference for the MV weaning and precocious recovery in IvIg group compared to PE group. 
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Guillain-Barré syndrome (GBS) is a demyelinating 
polyradiculoneuropathy with an acute paralysing disorder, typically 
symmetric and ascending and areflexia. Incidence varies between 
0.66 and 1.79 cases per 100 000 persons in general population [1-
6]. About pathogenesis, the aetiologies of GBS remain unclear; 
however, several findings suggest that causes such as an infection 
of the respiratory or gastrointestinal tract, vaccinations, surgery and 
pregnancy generate an abnormal immune response which leads to a 
destruction of myelin sheaths and/or axons [7-9]. The treatment is 
based on two mainstays: supportive care and immunomodulatory 
treatment. Supportive care prevents complications such as deep 
vein thrombosis, digestive bleeding and infections especially and 
physiotherapy. Both plasma exchange (PE) and intravenous 
immunoglobulins (IvIg) are the two immunomodulative treatment. 
Several studies demonstrated that IvIg and PE are efficacious 
treatment for GBS [10-13]. Our aim is to compare efficacy of IvIg 
versus PE in treatment of mechanically ventilation adults with GBS 





It is a prospective, monocentric non randomized study, realized in a 
medical ICU in Ibn Rochd university hospital of Casablanca which is 
a tertiary referring medical centre, during 5 years. We included all 
patients with GBS who required mechanical ventilation (MV). The 
diagnosis was according to clinical criteria [9]. We defined two 
groups: group 1 (group treated by IvIg: 0.4 g/kg/day during five 
days) and group 2 (group treated by PE: 4 PE during 10-14 days). 
The choice of treatment depends on the economic level of the 
patient and the presence or not of a contraindication to any of the 
treatments. We recorded data age, sex, origin of the patient, the 
reason for admission in ICU, results of CSF study, the mean length 
of hospitalization, duration of ventilation, the onset of motor 
recovery, complications and specific treatments including 
plasmapheresis, and IvIg. We also registered the findings of 
electrophysiological studies. The median interval between onset of 
neuropathy and performance of the electrophysiological study was 
7.5 days. All patients were ventilated using endotracheal mechanical 
ventilation then tracheotomised within the first week of 
hospitalization. Patients were intubated if they had SpO2 less than 
90 % in room air requiring increasing FiO2, or showed clinical 
symptoms of CO2 retention. When patients were able to trigger 
spontaneous breathing, they were changed to a pressure-support 
spontaneous ventilation mode. Pressure support was gradually 
decreased to 10 cmH2O. If secretions were manageable with good 
airway reflexes, a daily spontaneous breathing trial (SBT) was 
performed using a T-piece for 12 to 24 hours. Patients were 
extubated if SBT was successful. SBT was declared successful if 
there was no increased work of breathing or apnea, symptoms of 
hypercapnia, tachycardia and if SpO2 remained well compared to 
pre-SBT value. The quantitative variables are expressed on mean ± 
standard derivation and compared with Student tes. The statistic 
analysis has been based on SPSS 10.0 for windows. P < 0.05 is 





Between January 2006 and December 2010, 41 patients were 
enrolled, 21 in group 1 (IvIg group) and 20 in group 2 (PE group). 
No medical history was found in all patients. The mean age was 
37.4 ± 9.2 years, with a masculine predominance (75.4%). There 
was a statistically insignificant age between the two groups, 35.4 ± 
8.4 years for IvIg group versus 39.3 ± 5.2 years for PE group. 
Symptoms preceding the onset of GBS were fatigue in all patients, 
gastro-intestinal infections in 13 (32 %) patients and 
nasopharyngitis in 21 (51.2 %). The main initial sign was limb 
weakness followed by muscle pain in all patients and paresthesia in 
20 (49 %) patients. The mean time from the onset to the maximum 
of illness in all patients was 8.3 ± 4.2 days. There was no 
involvement of the cranial nerves in all patients. Autonomic 
dysfunction was reported in 20 (49 %) during hospitalisation such 
hypotension-hypertension and/or bradycardia and/or excessive 
sweating. The reason for admission in the ICU was respiratory 
impairment. Twenty eight patients were admitted from the 
emergency department, 13 patients were transferred from the 
department of neurology. Lumbar puncture was performed on all 
patients; the mean of CSF protein was elevated (0.95 ± 0.1 g/l) in 
29% of patients without CSF cell change. Based on 
electrophysiological findings, in 33 (80.5 %) patients had acute 
inflammatory demyelinating polyradiculoneuropathy (AIDP) and 
acute motor axonal neuropathy (AMAN) in 8 (19.5 %) patients. The 
mean length of hospitalization was 45.3 ± 9.2 days (range 30 to 
118 days). The ICU stay was significantly shorter (p=0.03) in the 
IvIg group than PE group. Patients receiving IvIg were early 
weaned of MV (p=0.01) compared to those receiving PE with a 
statistical significance. Also, the beginning of motility recuperation 
was significantly precocious (p=0.04) in IvIg group than PE group 






Our results suggest that IvIg is more benefit for our patients than 
PE. For the IvIg group, the ICU stay was shorter, weaned earlier of 
MV and the beginning of motility recuperation was precocious than 
PE group. According to two reviews published in the Cochrane 
library 2012, patients treated within two weeks from onset with IvIg 
had recovery as much as PE [14]; and compared to the 
symptomatic care alone, patients treated by PE had a good 
evolution [15]. However, some studies suggest that patients had 
IvIg treatment had more improvement than those had PE. Indeed, 
Kuwabara [16] and Van der Meché [12] showed that IvIg group had 
a significant fast evolution than PE group. Contrary, El-Bayoumi et 
al, in an infant population, found that the PE group had a significant 
shorter MV duration compared to IvIg group [17]. Finally, no 
significant difference between the two treatments showed by others 
authors [18-21]. Furthermore, other therapeutic options are under 
research such adapted IvIg dosage, complement inhibitors, selective 





Although the results of the literature are not conclusive, our work of 
which the most important slant is the absence of randomization, 
reveals that there is a meaningful difference for the MV weaning 
and a precocious recovery in IvIg group compared to the PE group. 
These encouraging results would merit to be confirmed by 
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Table 1: comparison of IvIg and PE groups regarding length of stay, beginning of motility recuperation and weaning of 
mechanical ventilation 
  Group 1 (IvIg) Group 2 (PE) p 
Length of stay in ICU (days) 38.2 ± 7.6 52.4 ± 5.3 0.03 
Beginning of motility recuperation (days) 10.43 18.74 0.04 
Weaning of mechanical ventilation (days) 18.72 38.52 0.01 
IvIg: intravenous immunoglobulin ; PE: plasma exchange 
 
 
